Skip to main content


Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Fig. 4

Sera of patients treated with AADvac1 recognise tau pathology in Alzheimer’s disease and Pick’s disease. af Alzheimer’s disease. gl: Pick’s disease. Sera of three different patients with different strengths of antibody responses (patient R17 with an anti-AD-tau titre of 1:30,999; patient R25 with 1:18,185; and patient R10 with 1:12,800) were used for staining. Staining with pre-treatment sera is shown as a negative control (df, jl)

Back to article page